Biocon`s arm gains on getting tentative nod for Rifaximin Tablets, 550 mg
Biocon is currently trading at Rs. 348.95, up by 1.70 points or 0.49% from its previous closing of Rs. 347.25 on the BSE.
The scrip opened at Rs. 347.80 and has touched a high and low of Rs. 350.85 and Rs. 347.70 respectively. So far 27193 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 405.90 on 18-Jul-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 352.85 and Rs. 340.20 respectively. The current market cap of the company is Rs. 46693.45 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.86% and 16.68% respectively.
Biocon’s wholly owned subsidiary -- Biocon Pharma in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from the U.S. Food and Drug Administration (USFDA) for the ANDA for Rifaximin Tablets, 550 mg.
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhea (IBS-D) in adults.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
